Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis
Copyright policy )Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis
ETI treatment reduces inflammatory markers and positive bacterial cultures on BAL in PwCF. These findings suggest that ETI has a greater impact on chronic infection and inflammation than ivacaftor alone. However, airway inflammation persists in a fraction of treated individuals, indicating an ongoing need to optimize other treatments in a subset of patients.
- University of North Carolina at Chapel Hill United States
- Carroll College United States
- University Medical Center United States
Pyrrolidines, Indoles, Cystic Fibrosis, Pyridines, Cystic Fibrosis Transmembrane Conductance Regulator, Quinolones, Aminophenols, Drug Combinations, Mutation, Humans, Pyrazoles, Benzodioxoles, Chloride Channel Agonists
Pyrrolidines, Indoles, Cystic Fibrosis, Pyridines, Cystic Fibrosis Transmembrane Conductance Regulator, Quinolones, Aminophenols, Drug Combinations, Mutation, Humans, Pyrazoles, Benzodioxoles, Chloride Channel Agonists
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).18 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!